| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 53.2 | 52.3 |
| Gross profit | 31.2 | 27.6 |
| Net income | -6.1 | -5.5 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +1.8% |
|---|---|
| Gross margin | 58.6% |
| Operating margin | -15.8% |
10-Q filed with the SEC, NASDAQ: CTKB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Cytek Biosciences, Inc.: key numbers
- Share price
- $5.63Close, Nov 16
- Market cap
- $736M
- Shares outstanding
- 130.78MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Laboratory Analytical InstrumentsSIC 3826
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Cytek Biosciences, Inc.
All →Cytek Biosciences Financial Results
Cytek Biosciences reported Q3 2026 revenue of $53.2 million, a 2% increase year-over-year, driven by 12% growth in the U.S. market and strong demand for high-end instruments. The company achieved a GAAP gross margin of 59% and narrowed its full-year 2026 revenue guidance to a range of $208 million to $211 million.
- Term
- Q3 2026
“We delivered another solid third quarter, with growth led by the U.S., where revenue grew 12%, and double-digit growth in our service business. Demand for our high-end instruments remained strong, with high-end Full Spectrum Profiling instrument revenue up 11% and Aurora Evo placements nearly doubling year over year. We also expanded gross margin by nearly 600 basis points. Looking ahead, we are reiterating the midpoint of our full-year revenue guidance and expect a strong finish to the year. We are well positioned to keep gaining market share, with our new product launches continuing to strengthen our technology leadership.”
Wenbin Jiang, CEO of Cytek Biosciences